SeaSpine Holdings Corporation (NASDAQ:SPNE) has earned an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $19.00.
SPNE has been the topic of several recent analyst reports. Zacks Investment Research raised SeaSpine from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Wednesday, November 8th. BTIG Research reaffirmed a “buy” rating on shares of SeaSpine in a report on Monday, November 6th. Ladenburg Thalmann Financial Services assumed coverage on SeaSpine in a report on Thursday, December 14th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of SeaSpine in a report on Friday, November 3rd.
Shares of SeaSpine (NASDAQ:SPNE) traded up $0.15 during trading hours on Monday, reaching $10.14. The company had a trading volume of 10,990 shares, compared to its average volume of 21,899. SeaSpine has a 1 year low of $6.31 and a 1 year high of $13.46. The company has a market capitalization of $136.17 and a PE ratio of -3.48.
ILLEGAL ACTIVITY NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/01/11/seaspine-holdings-corporation-spne-receives-19-00-average-price-target-from-analysts.html.
SeaSpine Company Profile
SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.
What are top analysts saying about SeaSpine? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SeaSpine and related companies.